BCL-2 is an anti-apoptotic agent that stabilizes the mitochondria and prevents the activation of the proteins that promote apoptosis.[77] Since BCL-2 is dysregulated in AML and its overexpression is what causes treatment resistance and a poor clinical outcome, it is a prospective therapeutic target.[78,79] The expression of Bcl-2 is necessary for AML cells to survive.[80] Bcl-2 protein overexpression, which is associated with chemotherapy resistance, shields cells from apoptosis.[81,82] Therefore, inhibiting anti-apoptotic Bcl-2 family members is hence potential for treating AML. Here, BCL2 is linked to acute myeloid leukemia.